ASCO 2017

Geneva banner

Event Date: 15 April

The 2017 American Society of Clinical Oncology (ASCO) Annual Meeting took place on 2–6 June 2017 at McCormick Place convention centre, Chicago, Illinois.

Boehringer Ingelheim presented overall survival analysis of the LUME-Meso trial, results of the Phase III LUX-Head and Neck 2 trial and results of the first-in-man Phase I trial of the novel BET inhibitor, BI894999 . For more details, please see below. The full ASCO 2017 programme can be found here .


Relevant oral presentation, Saturday 3 June 2017

Oral session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics




Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors. (Abstract 2504 )

Aftimos et al.

Relevant oral presentations, Monday 5 June 2017

Oral session: Head and Neck Cancer




LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). (Abstract 6001 )

Burtness et al.

Oral session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers



Hall B1

Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (Abstract 8506 )

Nowak et al.